NEWS・COLUMN
We send the latest information from SMC Laboratories.
Clear Negative Correlation Between FVC and Ashcroft Score in Bleomycin-Induced Lung Fibrosis Model
In preclinical drug development for fibrotic lung diseases, the ability to quantitatively and reproducibly assess disease severity is essential. At SMC Laboratories, we evaluated the relationship between lung function and histopathological fibrosis in the bleomycin-induced lung fibrosis mouse model. Specifically, we analyzed the correlation between forced vital capacity (FVC) and the Ashcroft histological fibrosis score….
New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model
SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachloride)-induced acute liver injury model. This model reproduces acute hepatocellular injury and is well-suited for the non-clinical evaluation of compounds with hepatoprotective or anti-inflammatory properties. Following a single intraperitoneal administration of CCl₄, serum ALT and AST levels…
Launch of Rat Disease Model Services
To better meet evolving research needs, SMC Laboratories has officially launched a lineup of preclinical rat disease models across multiple therapeutic areas. ■ Background of Rat Model Introduction We have observed a significant rise in inquiries for rat-based studies due to the following reasons: Larger body size of rats allows for increased sample volume per…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH patients, changes in the microbiome and increased intestinal permeability (Leaky Gut) have been observed (Lixin et al., Hepatology, 2012; Jay et al., CMGH, 2015). In fact, analyses in mouse models have shown that dysfunction of the gut-liver axis, such…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Roflumilast) in a drug efficacy evaluation study using porcine pancreatic elastase (PPE)-induced COPD model. The drug used as a positive control is roflumilast, a PDE-4 inhibitor. Mean linear intercept by histological analysis of the lungs, the…
The STAM™ mouse: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad Sci U S A. 2018). Title: Integrative genomic analysis of mouse and human hepatocellular carcinoma Dow, et al. Proc Natl Acad Sci U S A. 2018 The STAM™ model is a…
Introducing our skin disease model: Imiquimod (IMQ)-induced psoriasis model
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatitis model for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin. It is…
MOA demonstration #3 【GLP-1】｜Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-1, Wegovy® (semaglutide), approved by the FDA for the treatment of obesity, is a GLP-1 receptor agonist. GLP-1 receptor agonists such as semaglutide were initially developed for the treatment of diabetes, but drug discovery research has been conducted to expand…
Custom Model Service and its case study “CAIA-Rheumatoid Arthritis Model”
In recent years, we have received many requests about our services, starting from the establishment of pathological models, in response to the increasing diversity of diseases and the needs for therapeutic drug development. Therefore, today we would like to introduce an example study regarding custom model services, for which we have received many inquiries. …
MOA demonstration #2【diponectin】｜A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as MOA. Demonstration of adiponectin-derived peptide ALY688 in a drug evaluation study using STAM™ mice ►The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online…
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound's efficacy. In addition to molecular targeted drugs such as lenvatinib and sorafenib, immune checkpoint…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in humans. If you are considering using a mouse model of pulmonary fibrosis for drug evaluation studies, then using a suitable study design allows you to best evaluate the efficacy of your compound. As mentioned in a previous news,…